The American Journal of Medicine
Volume 123, Issue 6 , Pages 484-488, June 2010

Improving Stroke Risk Stratification in Atrial Fibrillation

  • Gregory Y.H. Lip, MD

      Affiliations

    • University of Birmingham Centre for Cardiovascular Sciences, City Hospital, Birmingham, England
    • Corresponding Author InformationReprint requests should be addressed to Gregory Y. H. Lip, MD, University of Birmingham Centre for Cardiovascular Sciences City Hospital, Birmingham B18 7QH, United Kingdom
  • ,
  • Jonathan L. Halperin, MD

      Affiliations

    • The Cardiovascular Institute, Mount Sinai Medical Center, New York, New York

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 30.00 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.

 Funding: None.

 Conflict of Interest: Dr Lip has received funding for research, consultancy, and lecturing from different manufacturers of drugs used for the treatment of atrial fibrillation, including AstraZeneca, Bayer, Boehringer Ingelheim, Astellas, Sanofi-Aventis, and Daichii-Sankyo. Dr Halperin has received consulting fees from Astellas Pharma, Bayer HealthCare, Biotronik, Boehringer Ingelheim, Daiichi Sankyo, Johnson & Johnson, and Sanofi-Aventis, and an honorarium from Portola Pharmaceuticals for data safety monitoring activities.

 Authorship: All authors had access to the data and played a role in writing this manuscript.

PII: S0002-9343(09)01151-6

doi:10.1016/j.amjmed.2009.12.013

The American Journal of Medicine
Volume 123, Issue 6 , Pages 484-488, June 2010